Risk Stratification Tools and Prognostic Models in Non-muscle-invasive Bladder Cancer: A Critical Assessment from the European Association of Urology Non-muscle-invasive Bladder Cancer Guidelines Panel

被引：68

作者：

Soukup, Viktor ^{[1
,2
]}

Capoun, Otakar ^{[1
,2
]}

Cohen, Daniel ^{[3
]}

Hernandez, Virginia ^{[4
]}

Burger, Maximilian ^{[5
]}

Comperat, Eva ^{[6
]}

Gontero, Paolo ^{[7
]}

Lam, Thomas ^{[8
]}

Mostafid, A. Hugh ^{[9
]}

Palou, Joan ^{[10
]}

van Rhijn, Bas W. G. ^{[11
]}

Roupret, Morgan ^{[12
]}

Shariat, Shahrokh F. ^{[13
]}

Sylvester, Richard ^{[14
]}

Yuan, Yuhong ^{[15
]}

Zigeuner, Richard ^{[16
]}

Babjuk, Marek ^{[17
,18
]}

机构：

[1] Charles Univ Prague, Dept Urol, Gen Teaching Hosp, KeKarlovu 6, Prague 12808 2, Czech Republic

[2] Charles Univ Prague, Fac Med 1, KeKarlovu 6, Prague 12808 2, Czech Republic

[3] Royal Free London NHS Fdn Trust, Dept Urol, London, England

[4] Hosp Univ Fdn Alcorcon, Dept Urol, Madrid, Spain

[5] Julius Maximilians Univ Wurzburg, Dept Urol & Paediat Urol, Wurzburg, Germany

[6] Sorbonne Univ, Hop Tenon, AP HP, Dept Pathol,Inst Univ Cancerol GRC5, Paris, France

[7] Univ Turin, Dept Surg Sci, Urol, Turin, Italy

[8] Univ Aberdeen, Acad Urol Unit, Aberdeen, Scotland

[9] Royal Surrey Cty Hosp, Dept Urol, Guildford, Surrey, England

[10] Univ Autonoma Barcelona, Dept Urol, Fundacio Puigvert, Barcelona, Spain

[11] Antoni van Leeuwenhoek Hosp, Netherlands Canc Inst, Dept Surg Oncol Urol, Amsterdam, Netherlands

[12] Sorbonne Univ, Hop Pitie Salpetriere, AP HP, Dept Urol,Inst Univ Cancerol GRC5, Paris, France

[13] Med Univ Vienna, Vienna Gen Hosp, Dept Urol, Vienna, Austria

[14] European Assoc Urol, EAU Guidelines Off Board, Arnhem, Netherlands

[15] McMaster Univ, Hlth Sci Ctr, Dept Med, Hamilton, ON, Canada

[16] Med Univ Graz, Dept Urol, Graz, Austria

[17] Charles Univ Prague, Motol Univ Hosp, Dept Urol, Prague, Czech Republic

[18] Charles Univ Prague, Fac Med 2, Prague, Czech Republic

来源：

EUROPEAN UROLOGY FOCUS | 2020年 / 6卷 / 03期

关键词：

Bladder cancer; Prognosis; Recurrence; Progression; Risk stratification; Scoring system; Scoring model; Risk; PREDICTING RECURRENCE; UROTHELIAL CARCINOMA; EXTERNAL VALIDATION; TRANSURETHRAL RESECTION; JAPANESE PATIENTS; CHINESE PATIENTS; EAU GUIDELINES; SCORING MODEL; STAGE TA; PROGRESSION;

D O I：

10.1016/j.euf.2018.11.005

中图分类号：

R5 [内科学]; R69 [泌尿科学（泌尿生殖系疾病）];

学科分类号：

1002 ; 100201 ;

摘要：

Context: This review focuses on the most widely used risk stratification and prediction tools for non-muscle-invasive bladder cancer (NMIBC). Objective: To assess the clinical use and relevance of risk stratification and prediction tools to enhance clinical decision making and counselling of patients with NMIBC. Evidence acquisition: The most frequent, currently used risk stratification tools and prognostic models for NMIBC patients were identified by the members of the European Association of Urology (EAU) Guidelines Panel on NMIBC. Evidence synthesis: The 2006 European Organization for Research and Treatment of Cancer (EORTC) risk tables are the most widely used and validated tools for risk stratification and prognosis prediction in NMIBC patients. The EAU risk categories constitute a simple alternative to the EORTC risk tables and can be used for comparable risk stratification. In the subgroup of NMIBC patients treated with a short maintenance schedule of bacillus CalmetteGuerin (BCG), the Club Urologico Espanol de Tratamiento Oncologico (CUETO) scoring model is more accurate than the EORTC risk tables. Both the EORTC risk tables and the CUETO scoring model overestimate the recurrence and progression risks in patients treated according to current guidelines. The new concept of conditional recurrence and progression estimates is very promising during follow-up but should be validated. Conclusions: Risk stratification and prognostic models enable outcome comparisons and standardisation of treatment and follow-up. At present, none of the available risk stratification and prognostic models reflects current standards of treatment. The EORTC risk tables and CUETO scoring model should be updated with previously unavailable data and recalculated. Patient summary: Non-muscle-invasive bladder cancer is a heterogeneous disease. A risk-based therapeutic approach is recommended. We present available risk stratification and prediction tools and the degree of their validation with the aim to increase their use in everyday clinical practice. (c) 2018 European Association of Urology. Published by Elsevier B.V. All rights reserved.

引用

页码：479 / 489

页数：11

共 56 条

[1] The Efficiency of the EORTC Scoring System for the Prediction of Recurrence and Progression of Non-muscle-invasive Bladder Cancer Treated by Bacillus Calmette-Guerin Immunotherapy [J].

Ajili, Faouzia ;

Darouiche, Amine ;

Chebil, Mouhamed ;

Boubaker, Samir .

ULTRASTRUCTURAL PATHOLOGY, 2013, 37 (04) :249-253

[2] Long-term prognostic value of the combination of EORTC risk group calculator and molecular markers in non-muscle-invasive bladder cancer patients treated with intravesical Bacille Calmette-Guerin [J].

Alkhateeb, Sultan S. ;

Neill, Mischel ;

Bar-Moshe, Sas ;

Van Rhijn, Bas ;

Kakiashvili, David M. ;

Fleshner, Neil ;

Jewett, Michael ;

Petein, Michel ;

Schulman, Claude ;

Hanna, Sally ;

Bostrom, Peter J. ;

Roumeguere, Thierry ;

Shariat, Shahrokh F. ;

Rorive, Sandrine ;

Zlotta, Alexandre R. .

UROLOGY ANNALS, 2011, 3 (03) :119-126

[3] External validation of EORTC risk scores to predict recurrence after transurethral resection of brazilian patients with non-muscle invasive bladder cancer stages Ta and T1 [J].

Almeida, Gilberto L. ;

Busato, Wilson F. S., Jr. ;

Ribas, Carmen Marcondes ;

Ribas-Filho, Jurandir Marcondes ;

De Cobelli, Ottavio .

INTERNATIONAL BRAZ J UROL, 2016, 42 (05) :932-941

[4] Recurrence and Progression in Non-Muscle-Invasive Bladder Cancer Using EORTC Risk Tables [J].

Altieri, Vincenzo Maria ;

Castellucci, Roberto ;

Palumbo, Pietro ;

Verratti, Vittore ;

Sut, Michal ;

Olivieri, Raffaella ;

Manco, Rossella ;

Ricciardulli, Stefano ;

Nicolai, Michele ;

Criniti, Pasquale ;

Tenaglia, Raffaele Lanfranco .

UROLOGIA INTERNATIONALIS, 2012, 89 (01) :61-66

[5]

[Anonymous], GUIDELINES NONMUSCLE

[6]

[Anonymous], [No title captured]

[7]

Ather MH, 2009, UROL J, V6, P189

[8] EAU guidelines on non-muscle-invasive urothelial carcinoma of the bladder [J].

Babjuk, Marko ;

Oosterlinck, Willem ;

Sylvester, Richard ;

Kaasinen, Eero ;

Boehle, Andreas ;

Palou-Redorta, Juan .

EUROPEAN UROLOGY, 2008, 54 (02) :303-314

[9] EAU Guidelines on Non-Muscle-invasive Urothelial Carcinoma of the Bladder: Update 2016 [J].

Babjuk, Marko ;

Boehle, Andreas ;

Burger, Maximilian ;

Capoun, Otakar ;

Cohen, Daniel ;

Comperat, Eva M. ;

Hernandez, Virginia ;

Kaasinen, Eero ;

Palou, Joan ;

Roupret, Morgan ;

van Rhijn, Bas W. G. ;

Shariat, Shahrokh F. ;

Soukup, Viktor ;

Sylvester, Richard J. ;

Zigeuner, Richard .

EUROPEAN UROLOGY, 2017, 71 (03) :447-461

[10]

Bagnall P., 2015, Bladder cancer: diagnosis and management

← 1 2 3 4 5 6 →